CLAIMS

1. A compound of general formula (II), a stereoisomer or a pharmaceutically acceptable salt thereof:



(II)

X_1, X_2 and X_3 are all CH;

L_1 is selected from $-CH_2-$, $-CD_2-$ and $-CH_2O-$;

R_1 is selected from $-(CH_2)_{n5}O(CH_2)_{n6}R_{A2}$;

R_7 is selected from chlorine, or bromine;

R_8 is selected from methyl;

R_{A2} is selected from C_{1-3} alkyl, C_{1-3} deuteroalkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4- to 7-membered heterocyclyl, C_{3-6} cycloalkyl C_{1-3} alkyl and 4- to 7-membered heterocyclyl C_{1-3} alkyl;

n5 and n6 are 0, 1, 2 or 3.

2. The compound, or the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 1, characterized in that the compound is further represented by (II-1):



(II-1)

L_1 is selected from $-CH_2-$ or $-CD_2-$;

R_1 is selected from $-(CH_2)_{n5}O(CH_2)_{n6}R_{A2}$;

R_7 is selected from chlorine, or bromine;

R_8 is selected from methyl;

R_{A2} is selected from C_{1-3} alkyl, C_{1-3} deuteroalkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4- to 7-membered heterocyclyl, C_{3-6} cycloalkyl C_{1-3} alkyl and 4- to 7-membered heterocyclyl C_{1-3} alkyl;

n5 is 0, 1, 2 or 3; and

n6 is 0, 1 or 2.

3. The compound, or the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 2, characterized in that,

R_1 is selected from , , , , , , , , , , , , and .

4. A compound, or a stereoisomer or a pharmaceutically acceptable salt thereof, which is:





5. A compound, or a stereoisomer or a pharmaceutically acceptable salt thereof, which is:



6. A compound of general formula (M-1) or (M-2), a stereoisomer or a pharmaceutically acceptable salt thereof:



(M-1) **(M-2)**

wherein L_1, X_1, X_2, X_3, R_1, R_7, and R_8 are as defined in claim 1;

R_9 is selected from ;

Pg is selected from (trimethylsilyl)ethoxymethyl or methoxymethylether.

7. A method for preparing the compound, or the stereoisomer or the pharmaceutically acceptable salt thereof according to claim 1, characterized in that the method comprises the following steps:



reacting a compound of general formula (M-1) with a compound of general formula (M-3) to obtain a compound of general formula (M-2), and deprotecting the compound of general formula (M-2) to obtain a compound of general formula (II),

wherein L_1, X_1, X_2, X_3, R_1, R_7, and R_8 are as defined in claim 1;

$R^{2'}$ is selected from , chlorine or bromine;

R_9 is selected from , chlorine or bromine;

Pg is selected from (trimethylsilyl)ethoxymethyl or methoxymethylether;

or



reacting a compound of general formula (M-4) with a compound of general formula (M-5) to obtain a compound of general formula (M-2), and deprotecting the compound of general formula (M-2) to obtain a compound of general formula (II),

wherein L_1, X_1, X_2, X_3, R_1, R_7, and R_8 are as defined in claim 1;

$R^{1'}$ is selected from methanesulfonyloxy or bromine;

Pg is selected from (trimethylsilyl)ethoxymethyl or methoxymethylether.

8. A pharmaceutical composition comprising a therapeutically effective dose of the compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, and one or more pharmaceutically acceptable carriers or excipients.

9. Use of the compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, and the pharmaceutical composition according to claim 8 in the preparation of a drug for treating an angiotensin II-dependent or endothelin-dependent disease; particularly, in the

preparation of a drug for treating a dual-acting angiotensin-dependent and endothelin-dependent disease.

10. Use of the compound, the stereoisomer or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, and the pharmaceutical composition according to claim 8 in the preparation of a drug for treating pain, sexual dysfunction, hypoxia and an ischemic disease, dementia, a neurological disease, a liver disease, a cancer, hypertension, diabetes or a kidney disease, wherein the kidney disease is selected from a disease or a condition related to kidney, glomerular or glomerular mesangial cell function.

11. The use according to claim 10, characterized in that the kidney disease is selected from focal segmental glomerulosclerosis or IgA nephropathy.